First County Bank CT Acquires New Position in Sanofi (NASDAQ:SNY)

First County Bank CT bought a new stake in shares of Sanofi (NASDAQ:SNY - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 7,972 shares of the company's stock, valued at approximately $442,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in SNY. Barclays PLC lifted its position in Sanofi by 107.5% during the third quarter. Barclays PLC now owns 639,772 shares of the company's stock valued at $36,869,000 after purchasing an additional 331,445 shares during the period. Brighton Jones LLC lifted its position in Sanofi by 52.6% during the fourth quarter. Brighton Jones LLC now owns 5,420 shares of the company's stock valued at $261,000 after purchasing an additional 1,869 shares during the period. R Squared Ltd acquired a new position in Sanofi during the fourth quarter valued at $202,000. Synergy Asset Management LLC acquired a new position in Sanofi during the fourth quarter valued at $25,000. Finally, Abel Hall LLC lifted its position in Sanofi by 1.8% during the fourth quarter. Abel Hall LLC now owns 10,990 shares of the company's stock valued at $530,000 after purchasing an additional 194 shares during the period. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SNY. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. BNP Paribas initiated coverage on shares of Sanofi in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective for the company. Three analysts have rated the stock with a hold rating, two have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat, Sanofi currently has an average rating of "Buy" and an average target price of $63.33.

Sanofi Price Performance

Shares of Sanofi stock traded down $2.95 during trading hours on Friday, reaching $49.40. The stock had a trading volume of 4,670,469 shares, compared to its average volume of 2,402,932. The firm has a market capitalization of $121.15 billion, a PE ratio of 19.84, a PEG ratio of 1.01 and a beta of 0.55. The stock's 50 day moving average is $52.25 and its 200 day moving average is $51.92. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The company's quarterly revenue was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.78 earnings per share. Equities analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently announced an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a dividend yield of 3.1%. This is a boost from Sanofi's previous annual dividend of $1.48. Sanofi's payout ratio is currently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.